Completion of Licensor Succession for mRNA-based ERA Platform Technology Transfer Agreement (Total USD 239M)
- Daewoong Pharma has acquired the mRNA-based ERA (Epigenetic Reprogramming of Aging) platform technology and assets from Turn Biotechnologies, and completed succession of the licensor position in the existing joint development and license agreement with Hanall Biopharma.
- Total contract value is up to USD 239M (USD 1M upfront, USD 238M development/regulatory/sales milestones, separate royalties); actual revenue depends on clinical and regulatory progress.
- The succession was finally agreed on May 20, 2026; the auction win occurred on May 6, 2026 (US time).
- This secures Daewoong Pharma's right to receive milestones and royalties from Hanall Biopharma.
ADVERTISEMENT (250px+)
KOSPI Filing Information
- Filing: [Correction of Description] Major Management Matters Related to Investment Decision (Succession of Status of Technology Transfer Contract for mRNA-based Epigenetic Reprogramming of Aging (ERA))
- Company: Daewoong Pharma (069620)
- Submission: Daewoong Pharma
- Receipt: 05-20-2026
- Under KRX KOSPI Market Division